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In humans and other mammals, plasmacytoid 
DCs (pDCs) are specialized immune cells that 
selectively express Toll-like receptor (TLR) 7 
and TLR9, which are key endosomal sensors 
of microbial and self-RNA or DNA, respec-
tively (Jarrossay et al., 2001; Kadowaki et al., 
2001; Liu, 2005; Gilliet et al., 2008). Activa-
tion of TLR7 or TLR9 by nucleic acids in 
pDCs triggers signal transduction, leading to 
rapid and robust secretion of type I IFN, inflam-
matory cytokines, and chemokines (Colonna 
et  al.,  2004;  Honda  and  Taniguchi,  2006; 
Kawai and Akira, 2006; Piqueras et al., 2006; 
Gilliet et al., 2008). The TLR-induced IFN 
response is regulated by several immunorecep-
tor  tyrosine-based  activation  motif  (ITAM)–
bearing signaling receptors on pDCs (Novak 
et al., 2004; Fuchs et al., 2005; Blasius et al., 
2006a; Cao et al., 2006, 2007; Röck et al., 
2007; Cho et al., 2008; Gilliet et al., 2008). 
One such receptor is ILT7, a member of the 
Ig-like transcript (ILT) family (also known as 
leukocyte Ig-like receptors) found in humans 
and primates (Brown et al., 2004).
ILTs, which are expressed by a variety of 
immune cell types, are comprised of a group of 
inhibitory receptors bearing immunoreceptor 
tyrosine-based inhibitory motifs and a group 
of stimulatory receptors that signal through 
their association with adaptor molecules con-
taining ITAM (Brown et al., 2004). ILT7, also 
known as LILRA4 and CD85g, contains four 
extracellular Ig-like domains and a positively 
charged residue within the transmembrane re-
gion, allowing ILT7 to form a receptor complex 
with a signaling adaptor FcRI. Uniquely   
expressed by human pDCs, ILT7 suppresses 
TLR7/9-induced  type  I  IFN  secretion  by 
pDCs when cross-linked by anti-ILT7 mAbs 
that trigger signaling activation (Cao et al., 2006; 
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Plasmacytoid dendritic cells (pDCs) produce copious type I interferon (IFN) upon sensing 
nucleic acids through Toll-like receptor (TLR) 7 and TLR9. Uncontrolled pDC activation and 
IFN production are implicated in lymphopenia and autoimmune diseases; therefore, a 
mechanism controlling pDC IFN production is essential. Human pDCs specifically express an 
orphan receptor, immunoglobulin-like transcript 7 (ILT7). Here, we discovered an ILT7 
ligand expressed by human cell lines and identified it as bone marrow stromal cell antigen 2 
(BST2; CD317). BST2 directly binds to purified ILT7 protein, initiates signaling via the  
ILT7–FcRI complex, and strongly inhibits production of IFN and proinflammatory cyto-
kines by pDCs. Readily induced by IFN and other proinflammatory cytokines, BST2 may 
modulate the human pDC’s IFN responses through ILT7 in a negative feedback fashion.
© 2009 Cao et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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Identification of ILT7-L
To facilitate the identification of the putative ILT7-L, we 
immunized mice with T47D (ILT7-Lpos) and MDA-MB-231 
(ILT7-Lneg)  cells  and  obtained  multiple  hybridoma  clones 
that bound specifically to T47D cells, but not to MDA-MB-231 
cells. To identify mAbs that specifically recognize ILT7-L, 
we further screened the hybridoma clones for the ability   
to block T47D-induced ILT7 reporter cell activation. Two 
such clones (26F8 and 28G4) were identified (Fig. 2 A).
Using flow cytometry, we found that these two mAbs 
stained the breast tumor cell lines MDA-MB-468, MCF7, 
and T47D, which activated ILT7 reporter cells, but mini-
mally reacted with breast tumor cell lines MDA-MB-231 and 
ZR-75-1, which failed to activate ILT7 reporters (Fig. 2 B). 
Other cell lines (e.g., HEK293, Vero, CHO, and Cos 7) that 
failed to activate the ILT7 reporter cells were not stained by 
either 26F8 or 28G4 (unpublished data). In addition, these 
two  mAbs,  but  not  the  isotype-matched  control  mAb, 
strongly inhibited the ability of the tumor cell line T47D to 
activate the ILT7 reporter cells in a dose-dependent fashion 
(Fig. 2 C). The two mAbs recognize nonoverlapping epit-
opes, because one did not block the binding of the other to 
T47D cells, as determined by flow cytometry (unpublished 
data). Nevertheless, 26F8 and 28G4 mAbs immunoprecipi-
tated three similar protein bands in T47D cells, but not in 
MDA-MB-231 cells (Fig. 2 D), suggesting the presence of   
cellular proteins as the potential ligand for ILT7.
To identify the ligand for ILT7, 26F8 and 28G4 mAbs 
were used to screen a human cDNA library. Both antibodies 
specifically recognized the gene product of human BST2 
(CD317). BST2 is a 180-aa glycoprotein that was initially 
identified as a membrane protein expressed by bone marrow 
stromal cells and later shown to be expressed by plasma cells 
and multiple types of cancer cells (Ohtomo et al., 1999; 
Kupzig, 2003; Walter-Yohrling et al., 2003). BST2 is report-
edly expressed on many different types of cells after exposure 
to IFN- (Blasius et al., 2006b; Neil et al., 2008; Van Damme 
et al., 2008).
BST2 is an ILT7 ligand
The 26F8 and 28G4 mAbs stained the human BST2 cDNA-
transfected HEK293 cells, but not mock-transfected cells, 
by flow cytometry (Fig. 3 A). In addition, recombinant 
ILT7 protein directly bound to a recombinant BST2-GST 
fusion protein, but not GST protein, in a dose-dependent 
manner (Fig. 3 B). Specific interaction between recombi-
nant BST2-Fc and ILT7-Fc with an estimated affinity of 
106 M was detected by surface plasma resonance with 
Biacore, an interaction that was completely neutralized by 
26F8 mAb (Fig. 3 C).
Furthermore,  rBST2-GST  fusion  protein,  but  not  GST 
alone, strongly activated the ILT7 reporter cells (Fig. 4 A). The 
specificity of the BST2–ILT7 interaction was demonstrated 
by the findings that rBST2-GST failed to induce GFP expres-
sion in ILT7-negative reporter cells and that BST2-induced 
GFP expression in the ILT7 reporter cells was abrogated by 
Cho et al., 2008). Although several members of the inhibi-
tory ILT family regulate innate and adaptive immune re-
sponses  through  interaction  with  classical  and  nonclassical 
MHC class I ligands or virus-encoded MHC class I–like proteins 
(Chapman et al., 1999; Brown et al., 2004), the natural li-
gands for the stimulatory ILTs, including ILT7, are unknown.
Here, we report the identification of a surface molecule 
named bone marrow stromal cell antigen 2 (BST2) as a bio-
logical ligand for ILT7 and provide evidence that BST2–ILT7 
engagement may serve as a force to negatively regulate human 
pDCs’ innate immune functions, likely during inflammation, 
in a negative feedback manner.
RESULTS
Human cancer cells express novel ILT7 ligand
Previously, we constructed an NFAT-GFP reporter cell line 
expressing ILT7 and FcRI that expresses GFP in response 
to ILT7 surface ligation (Cao et al., 2006). To detect the 
presence of ILT7 ligands (ILT7-L), we used these cells to 
screen virus-infected cells and a large panel of human tumor 
cell lines. Co-culture of the ILT7 reporter cells with human 
breast carcinoma MDA-MB-468, MCF7, and T47D cells, 
but not with MDA-MB-231 or ZR-75-1 cells, induced GFP 
expression by the reporter cells (Fig. 1 A). We further tested 
several human ovarian, colon, melanoma, glioma, and lung 
cancer cell lines and found that two melanoma lines, WM35 
and Mel938, were able to similarly activate the ILT7 reporter 
cells (Fig. 1 B). Other transformed cell lines, such as HEK293, 
Vero, CHO, Cos7, and Jurkat, were unable to stimulate the 
ILT7 reporter cells (unpublished data).
As the breast cancer line T47D is most potent in trigger-
ing ILT7, we further characterized these cells. The ability of 
T47D cells to activate the reporter cells is ILT7 dependent 
because NFAT-GFP reporter cells expressing only the sig-
naling adaptor FcRI, and not ILT7, were not activated 
(Fig. 1 A). In addition, the induction of GFP was completely 
abolished by a neutralizing anti-ILT7 mAb (Fig. 1 C). Pre-
treatment with IFN- and TNF- enhanced the ability of 
the breast cancer MDA-MB-468 cells to activate the ILT7 
reporters (Fig. 1 D), suggesting that ILT7-L expression is regu-
lated by immune responses.
ILT7 activation by cancer cells requires direct cell–cell 
contact as cells cultured in separate chambers of a transwell 
dish fail to induce GFP (unpublished data). Although the 
two other ILT family members, ILT2 and ILT4, bind to 
the classical and nonclassical MHC class I (MHC-I) ligands 
(Navarro et al., 1999; Brown et al., 2004), the putative 
ILT7-L appears to be unrelated to MHC class I or class II 
because antibodies against human MHC class I or class II 
did not block the ability of T47D cells to activate the ILT7 
reporter cells (unpublished data), and both the MHC class 
I–expressing  cell  lines  (e.g.,  Jurkat  and  MDA-MB-231) 
and the MHC class II–expressing cell lines (e.g., EBV-
transformed B cells) were unable to activate ILT7 reporter 
cells (unpublished data).JEM VOL. 206, July 6, 2009 
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activation of the ILT7 reporter was blocked by neutralizing 
antibodies against either ILT7 or BST2 (Fig. 4 B). These data 
identify BST2 as a physiological ligand that specifically binds 
and activates ILT7.
neutralizing antibodies against either ILT7 or BST2, but not   
by control antibody. More importantly, BST2 expressed on the 
surface of HEK293 cells induced GFP expression in ILT7 
reporter cells, but not in ILT7-negative reporter cells. Again, 
Figure 1.  Human tumor cell lines express a potential ligand for ILT7. (A) Five human breast cancer cell lines were co-cultured with either ILT7+ NFAT-GFP 
reporter cells or parental NFAT-GFP reporter cells. The percentages of GFP-positive reporter cells were analyzed. Data are representative of four independent 
experiments. (B) Human carcinoma cells were co-cultured with ILT7+ NFAT-GFP reporter cells. The percentages of GFP-positive reporter cells were analyzed. 
The categories of the cancer lines are as follows: OVCAR-3, SKOV-3, and DOV-13 (ovarian); HT-29 and HCT-116 (colon); WM35, WM239, MEL526, MEL624, 
MEL888, and MEL938 (melanoma); U87, LN229, and SNB19 (glioblastoma); A549 (lung cancer). Data are representative of two independent experiments. 
(C) T47D cells were co-cultured with ILT7+ NFAT-GFP reporter cells in the presence of 1 µg/ml of control IgG1 or anti-ILT7 mAb. The percentages of  
GFP-positive reporter cells were plotted. Data are representative of four independent experiments. (D) Breast cancer MDA-MB-468 cells were first cultured  
for 5 d in the presence of medium, 5 ng/ml of TNF- or 500 U/ml of IFN-, and then co-cultured with NFAT-GFP reporter cells. The percentages of GFP-
positive reporter cells were analyzed. Data are representative of four independent experiments. Error bars represent the mean ± the SEM.1606 REGULATION OF PDCS BY BST2–ILT7 INTERACTION | Cao et al.
including IFN1, IFN4, IFN8, and IFN-, plus IL-6, by 
pDCs (Fig. 5 C) when activated by TLR agonists. In con-
trast, BST2 did not alter expression of co-stimulatory mole-
cules, such as CD80 and CD86, by pDCs (Fig. 5, C and D). 
The effect of BST2-mediated IFN suppression was abolished 
when ILT7 was neutralized with anti-ILT7 mAb, but not 
with control IgG1, indicating a direct engagement between 
ILT7 and rBST2 (Fig. 5 E). Lastly, pDCs co-cultured with 
HEK293 cells expressing an HA-tagged BST2 secreted re-
duced levels of IFN- in response to Flu virus when com-
pared with pDCs in contact with untransfected HEK293 cells 
(Fig. 5 F), suggesting that the BST2–ILT7 interaction modu-
lates pDCs’ TLR-induced IFN responses.
BST2 expression by human cells and by pDCs
To understand the prevalence of BST2 expression on human 
cells in response to IFN treatment, we cultured embryonic 
BST2 negatively regulates the innate immune functions  
of human pDCs
As previously shown, antibody cross-linking of ILT7 can in-
duce prominent calcium influx in primary pDCs as a result of 
ITAM-mediated FcRI signaling (Cao et al., 2006; Cho   
et al., 2008). Similarly, a rBST2-Fc protein, but not a control Fc 
protein alone, induced calcium mobilization in human pDCs, 
which depends on the function of Syk (Fig. 5 A).
Because mAb cross-linking of ILT7 inhibits the immune 
response of pDCs, we investigated the effect of BST2 on 
TLR-induced cytokine responses by pDCs. Freshly isolated 
pDCs from human peripheral blood were preincubated with 
plate-bound rBST2-Fc protein or plate-bound Fc protein for 
30 min, and were then challenged with influenza virus (Flu) 
or CpG, which trigger TLR7 and TLR9, respectively. rBST2 
protein suppressed the secretion of IFN- and TNF- 
(Fig. 5 B), as well as the transcription of type I IFN subtypes, 
Figure 2.  Characterization of mAbs against a putative ILT7 ligand. (A) Culture supernatants from different hybridoma clones were included in 
the co-cultures of ILT7 reporter cells and T47D cells. The percentages of GFP-positive reporter cells were determined. Two clones able to inhibit GFP in-
duction are indicated (arrows). Anti-ILT7 mAb (clone 17.2) was included as a positive control. (B) Five human breast cancer cells were stained with mAb 
26F8 (red line) or an isotype-matched control mAb (shaded area) and analyzed by flow cytometry. A similar result obtained with mAb 28G4 is not 
shown. Data are representative of three independent experiments. (C) T47D cells were co-cultured with ILT7 reporter cells in the presence of control 
IgG1, 26F8, or 28G4 mAbs at different concentrations. The percentages of GFP-positive reporter cells were plotted. Data are representative of four inde-
pendent experiments. (D) Surface biotinylated MDA-MB-231 and T47D were immunoprecipitated with control IgG1, 26F8, or 28G4. The precipitated 
proteins were analyzed by Western blotting with NeutrAvidin-HRP. Arrows indicate the specific protein bands obtained from T47D cells. Data are repre-
sentative of two independent experiments.JEM VOL. 206, July 6, 2009 
ARTICLE
1607
kidney HEK293 cells, dermal fibroblast line NHDF cells, 
human umbilical vein endothelial line HUVEC cells, and kera-
tinocyte line HaCat cells in the absence or presence of IFN-, 
and then analyzed BST2 surface expression by flow cytome-
try (Fig. 6 A). Although these cells minimally express BST2 
under normal conditions, IFN- treatment resulted in signif-
icant surface BST2 expression in all of them, which is consis-
tent with the reported IFN-mediated BST2 induction (Blasius 
et al., 2006b; Neil et al., 2008; Van Damme et al., 2008).
Interestingly, resting mouse pDCs prominently express 
BST2 (Blasius et al., 2006b), but lack the expression of a 
direct orthologue of ILT7 (Brown et al., 2004). However, 
low amounts of surface BST2 were detected on human 
pDCs that were freshly isolated or cultured with either TLR 
ligands or cytokines (Fig. 6 B), although BST2 transcripts 
were found elevated in TLR-activated pDCs (unpublished 
data).  To  investigate  a  potential  cis  interaction  between 
ILT7 and BST2, we transduced ILT7 and FcRI into a 
human Burkitt’s lymphoma cell line expressing endogenous 
BST2.  Interestingly,  expression  of  the  ILT7–FcRI 
complex, but not BDCA2–FcRI, another human pDC-
specific receptor complex, reduced the levels of surface 
BST2 (Fig. 6 C). Thus, ILT7–BST2 cis interaction likely 
results in BST2 internalization and might have functional 
consequences in human pDCs.
DISCUSSION
Here, we identify BST2 as a physiological ligand for a human 
pDC-specific receptor ILT7. pDCs play a critical role in an-
tiviral innate immune responses by secreting large quantities 
of IFN-/. However, the type 1 IFN responses immedi-
ately after viral infection are short lived; if not, massive and 
prolonged IFN exposure will damage hematopoiesis, leading 
to lymphopenia (Lin et al., 1998; Kamphuis et al., 2006), and 
increase the risk of autoimmunity (Gota and Calabrese, 2003). 
Hence, a mechanism ensuring a specific and transient IFN 
response to viruses is critical to minimize the possibility of 
lymphopenia and autoimmune diseases in the host. As BST2 
is well known to be robustly induced on the surface of vari-
ous types of cells after exposure to IFN and other proinflam-
matory cytokines via STAT activation (Ohtomo et al., 1999; 
Blasius et al., 2006b; Neil et al., 2008; Van Damme et al., 
2008), the BST2–ILT7 interaction, therefore, likely serves as 
an important negative feedback mechanism for preventing 
prolonged IFN production after viral infection (Fig. 7).
Intracellular TLRs have limited ability to discriminate 
host versus foreign nucleic acids (Haas et al., 2008). Several 
host factors, including anti-DNA antibodies, antimicrobial 
Figure 3.  BST2 directly binds to ILT7. (A) HEK293 cells transiently 
transfected with mock control or BST2 cDNA were analyzed by Western 
blotting for BST2 protein expression. Transfected cells were stained with 
26F8 mAb and analyzed by flow cytometry. The staining profile with IgG 
isotype-matched control mAb is shown in the shaded area. Staining with 
28G4 mAb produced identical results (not depicted). Data are representa-
tive of five independent experiments. (B) Plate-coated GST or BST2-GST 
were incubated with different concentrations of recombinant ILT7-Fc and 
HRP-conjugated anti–human Fc. Shown is absorption at OD 450 nm for 
each sample after addition of Tetramethyl benzidine (TMB) substrate. Data 
are representative of three independent experiments. (C, top) Recombi-
nant BST2-Fc, precoated on the surface of Biacore sensor chips, was 
mixed with different concentrations of injected recombinant ILT7-Fc. The 
kinetic response data after subtracting the value from precoated Fc are 
shown. Also shown are control responses with Fc alone or buffer. 
(bottom) Precoated recombinant BST2-Fc was premixed with buffer, 
control IgG1, or anti-BST2 mAb 26F8 and then exposed to injected re-
combinant ILT7-Fc. The kinetic response data after subtracting the 
value from precoated Fc are shown. Data are representative of two 
independent experiments.
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of ILTs are largely unknown (Cosman et al., 1997; Brown 
et al., 2004). Structural analysis revealed significant differ-
ences in MHC class I–binding sites between the inhibitory 
and stimulatory ILTs (Shiroishi et al., 2006), suggesting dis-
tinct ligand recognition by the two groups of ILTs. Here, 
we used a NFAT-GFP reporter cell system that reliably 
senses ILT7 surface ligation in the presence of an ILT7   
ligand, which led to the positive identification of BST2, a 
glycoprotein unrelated to the MHC molecules. BST2 pro-
tein has a unique topology, containing an N-terminal trans-
membrane  domain  and  a  C-terminal  GPI  anchor,  and 
locates within the lipid raft microdomains on plasma mem-
brane (Kupzig, 2003). Further structural analysis of the bind-
ing interface between BST2 and ILT7 may shed light on 
the structural basis of ligand recognition by ILT7 and sti-
mulatory ILTs. The receptor-NFAT reporter system should 
be also useful for the identification of the relevant ligands 
for other ILT orphan receptors and a better understanding 
of ILT’s biological function.
As the innate immune system has widely adopted “paired 
receptors” to exert tight regulatory control, many of the in-
hibitory receptors participate in self tolerance by recogniz-
ing ubiquitously expressed endogenous molecules, whereas 
stimulatory receptors may recognize “alert” molecules that 
are up-regulated after viral infection or immune activation 
(Lanier, 2008; Yamada and McVicar, 2008). For example, 
Ly49A, a prototype inhibitory Ly49 receptor expressed on 
mouse NK cells, recognizes endogenous MHC-I molecule 
peptide LL37, or the nuclear DNA-binding protein HMGB1, 
alone or in combination, facilitate entry of self-DNA into 
the endosomes of pDCs, where they trigger TLR9 to induce 
type 1 IFN responses (Lande et al., 2007; Marshak-Rothstein 
and Rifkin, 2007; Tian et al., 2007). Similarly, autoanti-
body–self small nuclear ribonucleoprotein complexes can ac-
tivate TLR7 through FcRII to induce IFN (Vollmer et al., 
2005; Savarese et al., 2006). This might lead to the consti-
tutive activation of pDCs, which contributes to the auto-
immune pathology of systemic lupus erythematosus and 
psoriasis. It will be of further interest to study if the BST2–
ILT7–mediated controlling mechanism is breached in pa-
tients with systemic lupus erythematosus and psoriasis (Blanco 
et al., 2001; Lande et al., 2007; Marshak-Rothstein and 
Rifkin, 2007), which may provide an opportunity to de-
velop therapeutics to down-modulate pDC activation during 
autoimmune disease.
Interestingly, BST2 represents the first non–MHC class 
I–type ligand for a member of the ILT receptor family 
(Brown et al., 2004). By sequence analysis, human receptor 
ILTs are divided into two separate groups—five inhibitory 
ILTs  containing  intracellular  immunoreceptor  tyrosine-
based inhibitory motifs and six stimulatory ILTs that would 
couple with ITAM-bearing adaptors. The inhibitory ILTs, 
e.g., ILT2 and ILT4, recognize proteins encoded by many 
MHC class I alleles and UL18, which is a MHC-like mol-
ecule associated with human cytomegalovirus (Chapman   
et al., 1999). However, the ligands for the stimulatory group 
Figure 4.  BST2 binds and potently activates ILT7. (A) GST or BST2-GST protein was co-cultured with ILT7+ NFAT-GFP reporter cells. The percentages 
of GFP-positive reporter cells are shown. Neutralizing antibodies ILT7 (5 µg/ml) or 26F8 (25 µg/ml) or an IgG1 control antibody were included in the 
cultures, as indicated. Data are representative of four independent experiments. (B) HEK293 cells transiently transfected with mock control or BST2 cDNA 
were co-cultured with ILT7+ NFAT-GFP reporter cells. The percentages of GFP+ reporter cells are shown. Neutralizing antibodies ILT7 (5 µg/ml), 26F8  
(25 µg/ml), 28G4 (25 µg/ml), or control IgG1 were included in the cultures, as indicated. Data are representative of three independent experiments.JEM VOL. 206, July 6, 2009 
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Figure 5.  BST2 activates primary pDCs and inhibits IFN and cytokine production by pDCs. (A) pDCs were incubated with anti-ILT7, recombinant 
Fc, or BST2-Fc proteins and then analyzed for calcium influx. pDCs pretreated with 5 µM of Syk inhibitor were also analyzed. Data are representative of 
three independent experiments. (B) The amounts of secreted cytokines from pDCs cultured with plate-bound Fc or BST2-Fc are shown. pDCs were acti-
vated overnight with either 0.2 µM of CpG 2216 or MOI 6 of Flu. Data are representative of five independent experiments with ten donors. (C) The levels 
of gene transcripts from pDCs cultured with purified Fc or BST2-Fc are shown. The relative expression of each gene was normalized with S18 and calcu-
lated against the value obtained from normal total PBMCs. Data are representative of two independent experiments. (D) BST2 does not affect co-stimula-
tory molecule expression by pDCs. pDCs cultured with plate-bound Fc or BST2-Fc and then activated with 0.2 µM of CpG 2216 for 48 h. Surface levels of 
CD80 and CD86 are shown. Data are representative of two independent experiments. (E) pDCs preincubated with medium, 20 µg/ml of IgG1 or 20 µg/ml 
of neutralizing ILT7 mAb were cultured overnight with plate-bound Fc or BST2-Fc in the presence of CpG 2216. The amounts of secreted IFN- were mea-
sured by ELISA. Percent of BST2-mediated IFN- suppression was calculated as percent ratio of IFN- ([Fc minus BST2-Fc]/[Fc]) and plotted. Data are 
representative of two independent experiments with four donors. (F) The amounts of secreted IFN- from Flu-challenged pDCs cultured with HEK293 
with or without surface HA-tagged BST2 are shown. Data are representative of two independent experiments.1610 REGULATION OF PDCS BY BST2–ILT7 INTERACTION | Cao et al.
infections (Ebihara et al., 2007). The fact that BST2 is a gene 
product whose expression is under control of inflammatory 
signals is consistent with the notion that stimulatory receptors 
may regulate immune functions by interacting with inducible 
or pathogen-associated ligands.
Like NK cells, pDCs express both inhibitory receptors and 
stimulatory receptors. Human pDC receptors ILT7, BDCA2, 
high-affinity Fc receptor for IgE, and NKp44, which all sig-
nal through an ITAM-mediated pathway, exert negative 
effects  on  the  pDC’s  IFN  response  to  TLR  activation   
(Dzionek et al., 2001; Novak et al., 2004; Fuchs et al., 2005; 
Cao et al., 2006, 2007). Similarly, activation of Siglec-H, in 
association with the ITAM-bearing DAP12 subunit, reduces 
type I IFN production by mouse pDCs in vitro and in vivo 
(Blasius et al., 2006a). On the other hand, Ly49Q, an inhibitory 
H-2Dd (Karlhofer et al., 1992), whereas stimulatory NK 
receptor Ly49H binds to glycoprotein M157 encoded by 
mouse cytomegalovirus (Arase et al., 2002; Smith et al., 2002), 
Ly49P recognizes the H-2Dk–restricted mouse cytomegalo-
virus–infected cells (Desrosiers et al., 2005), and NKG2D 
interacts with ligands with structural homology with MHC 
class I, including RAE-1-, H60, and MULT1 (Cerwenka 
et al., 2000; Diefenbach et al., 2001, 2003; Carayannopoulos 
et al., 2002), expression of which is under control of TLR 
activation, viral infections, and stress (Lodoen et al., 2003; 
Hamerman  et  al.,  2004;  Nice  et  al.,  2009).  In  human, 
NKG2D engages with MHC class I–like molecules MICA 
and MICB (Bauer et al., 1999), inducible by cell stress, and 
ULBP1-4 (Cosman et al., 2001; Chalupny et al., 2003), 
expression of which is influenced by TLR activation or viral 
Figure 6.  Analysis of BST2 expression and potential BST2–ILT7 cis-interaction. (A) HEK293, NHDF, HUVEC, and HaCat cells, cultured in the  
absence or presence of 500 units/ml of IFN- for 48 h, were stained with anti-BST2 mAb 26F8. Staining with isotype-matched control Ig is shown in the 
gray shaded area. Data are representative of three independent experiments. (B) Fresh isolated pDCs from peripheral blood or cells activated with various 
stimuli for 48 h were analyzed for surface BST2 expression by flow cytometry. Data are representative of two independent experiments. (C) Human  
Burkitt’s lymphoma Namalwa cells transduced with different pDC receptor complexes, i.e., BDCA2/FcRI or ILT7/FcRI, were analyzed for surface BST2 
and ILT7 expression. Data are representative of three independent experiments.JEM VOL. 206, July 6, 2009 
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MATERIALS AND METHODS
Reagents and cells. HEK293 cells were grown in high-glucose DME sup-
plemented with 10% FBS, 50 U/ml penicillin, and 50 µg/ml streptomycin. 
Breast cancer cells and mouse 2B4 NFAT-GFP reporter cells (Cao et al., 
2006) were grown in RPMI 1640 medium supplemented with 10% FBS and 
antibiotics. NHDF and HUVEC cells (Lonza) were cultured in Clonetics 
Fibroblast Cell Medium FGM-2 and Endothelial Cell Basal medium, respec-
tively, supplemented with growth factors following the manufacturer’s re-
commendations. HaCaT cells were provided by S. Ullrich (M.D. Anderson 
Cancer Center, Houston, TX) and cultured in RPMI 1640 medium supple-
mented with 10% FBS and antibiotics. Namalwa cells were cultured as pre-
viously described (Cao et al., 2007). Human TNF- was purchased from 
Peprotech. IFN- was purchased from Sigma-Aldrich.
ILT7 reporter cell assay. ELISA plates were coated with 10 µg/ml of 
protein in PBS or at the concentration specified. 105 cancer cells or trans-
fected HEK293 cells were seeded in 24-well plates the day before the exper-
iment. After 105 NFAT-GFP reporter cells were added to the ELISA plate 
or the cell monolayer, the plates were spun at 100 g for 2 min. After over-
night culture, cells were subjected to flow cytometric analysis to measure 
GFP expression.
BST2 activation of human primary pDCs. The institutional review 
board for human research at the M.D. Anderson Cancer Center approved 
the use of human blood samples for this study. Primary human pDCs were 
isolated from blood using a negative selection kit (Miltenyi Biotech) and 
sorted by flow cytometry as CD3CD11cCD14CD15CD16CD19C
D56CD4+CD123+ cells. pDCs were preincubated with plate-bound con-
trol Fc protein or BST2-Fc protein captured with 10 µg/ml of F(ab)2 goat 
anti–human IgG Fc (Jackson ImmunoResearch Laboratories) on an ELISA 
plate for 30 min before stimulation with 0.2 µM of CpG 2216 (Sigma-
Genosys) or heat-inactivated influenza virus PR8 at a multiplicity of infec-
tion (MOI) of 6. 18 h later, the supernatants were harvested and analyzed for 
cytokines, and the cells were lysed and RNA subjected to RT-PCR analysis, 
as previously described (Cao et al., 2006). To neutralize ILT7 in this assay, 
pDCs were preincubated with 20 µg/ml of anti-ILT7 (clone 17.2; Cao et al., 
2006), washed, and then incubated with plate-bound Fc or BST2-Fc and 
stimulated with CpG. In parallel, control pDCs were preincubated with 
medium or 20 µg/ml of IgG1, washed, and stimulated similarly on Fc- or 
BST2-Fc–coated plates. To perform pDC and BST2-transfectant cell co-
culture, pDCs were preincubated with inactivated influenza virus (MOI = 8) 
for 30 min, and cells were pelleted by centrifugation for 5 min at 500 g and 
added to parent HEK293 or BST2-HA–transfected HEK293 monolayers. 
Cells were packed briefly by centrifuging at 100 g for 2 min. 18 h later, the 
supernatants were harvested and analyzed for cytokine secretion. To study 
calcium influx, purified control Fc protein or BST2-Fc protein was incu-
bated with pDCs in the presence of goat anti–human Fc F(ab)2 (Jackson   
ImmunoResearch Laboratories). Dye loading and flow cytometric analysis 
were performed as previously described (Cao et al., 2006).
Anti–ILT7-L mAb generation. 6–8-wk-old BALB/c mice were immu-
nized with T47D and MDA-MB-231 cells by the alternate footpad method 
(Cao et al., 2006). Hybridoma clones secreting mAbs that specifically stained 
T47D cells, but not MDA-MB-231 cells, were expanded. They were further 
screened for their ability to block T47D-induced GFP expression from ILT7+ 
reporter cells. mAbs 26F8 (IgG1) and 28G4 (IgG2a) were affinity purified and 
fluorochrome conjugated using mAb conjugation kits (Invitrogen).
cDNA library screening. A library of human full-length cDNA clones 
was purchased from OriGene Technologies, Inc. Plasmid DNA was pre-
pared  using  the  Wizard  plus  miniprep  kit  (Promega).  For  transfection, 
HEK293 cells were seeded at 104 cells/well in 96-well plates. 0.6 µl of Fu-
gene 6 (Roche) was added to 15 µl of Opti-MEM (Invitrogen) and mixed 
with 10 µl of DNA from individual cDNA clone. After 15 min at room 
temperature, the mixture was added to cells. 48 h later, cells were centrifuged 
Ly49 receptor expressed on mouse pDCs, recognizes MHC 
class I molecules and enhances pDC’s innate immune re-
sponses (Tai et al., 2008). Thus, it appears that the so-called 
stimulatory receptors may exercise potent suppressive regula-
tory functions on the innate immunity of pDCs.
Immature pDCs have been found in the local tumor 
environment of patients with ovarian cancer (Zou et al., 2001; 
Wei et al., 2005), breast cancer (Treilleux et al., 2004), 
melanoma (Salio et al., 2003; Benitez-Ribas et al., 2006), 
leukemia  (Mohty  et  al.,  2001,  2004),  Kaposi’s  sarcoma 
(Della Bella et al., 2006), and head and neck squamous 
cell carcinoma (Hartmann et al., 2003). Although pDCs 
only infiltrate 13% of primary breast tumors, their pres-
ence strongly correlates with an adverse outcome of the 
disease (Treilleux et al., 2004). The breast cancer micro-
environment profoundly inhibits pDC’s innate immune 
functions  (Sisirak  et  al.,  2008).  Because  IFN-  is  well 
known to be required for deterring the growth of primary 
tumors (Wenzel et al., 2005; Dunn et al., 2006), BST2–
ILT7 interactions that suppress pDCs’ IFN responses may 
contribute to the tumor tolerance (Fig. 7). On the other 
hand, BST2 found in multiple cancer types was identified 
as a potent inducer of NF-B (Matsuda et al., 2003) and 
one of the candidate genes expressed in malignant cells 
that  promote  tumor  invasion  (Ohtomo  et  al.,  1999; 
Kupzig,  2003;  Walter-Yohrling  et  al.,  2003).  Thus, 
BST2–ILT7 interaction might be bidirectional in a cancer 
environment, and the consequence of ILT7 engagement 
on BST2-expressing tumor cells should be investigated in 
the future.
Figure 7.  A proposed model of BST2–ILT7 mediated regulation of 
pDC innate immune responses. (top) By sensing viral infection, pDCs 
can rapidly and rigorously produce large amounts of IFN-I via TLR7 or 
TLR9 activation. IFN-I then may induce the neighboring cells to express 
BST2, which in turn engages with ILT7 on pDCs to down-regulate the 
magnitude of IFN and cytokine responses in a negative feedback manner. 
(bottom) In a tumor environment where BST2 is endogenously expressed, 
infiltrating pDCs may be functionally suppressed to elicit normal IFN  
response to TLR ligands as a result of BST2–ILT7 interaction.1612 REGULATION OF PDCS BY BST2–ILT7 INTERACTION | Cao et al.
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at 200 g for 3 min before the media was removed. 5 µg/ml of mAbs 26F8 or 
28G4  was  added  and  mixed  with  Cy5-labeled  goat  anti-mIgG  (Jackson   
ImmunoResearch Laboratories). Cells were incubated at room temperature 
for 2 h in the dark and analyzed by using a fluorometric microvolume assay 
technology 8100 HTS system (Applied Biosystems).
BST2 transfection and expression analysis. HEK293 cells were trans-
fected with an expression plasmid containing the full-length human BST2 
cDNA (Open Biosystems) with lipofectamine (Invitrogen). 48 h later, cells 
were either lysed for Western blot analysis using a BST2-specific rabbit poly-
clonal  antibody  (FabGennix,  Inc.)  or  subjected  to  staining  with  fluoro-
chrome-conjugated  anti–ILT7-L  mAbs.  HEK293  cells  stably  expressing 
BST2-HA were transfected with pcDNA3-zeo-BST2-HA, selected with 
Zeocin, and sorted for high HA expression by flow cytometry.
Generation of recombinant ILT7 and BST2 fusion protein. The 
extracellular domain of ILT7 or extracellular domain of BST2 (excluding 
GPI anchor) were cloned into an expression vector containing a mutated 
human Fc fragment (Arase et al., 2002). HEK293 cells were transiently 
transfected with the expression plasmids or the empty vector to produce 
recombinant protein, which was purified by using a Protein A column (GE 
Healthcare). The extracellular domain of BST2 (excluding GPI anchor) 
was constructed as a GST-fusion protein, which was stably expressed in 
CHOK1SV cells and purified by glutathione–Sepharose affinity chroma-
tography (GE Healthcare).
Surface plasma resonance analysis. Surface plasma resonance was per-
formed using a Biacore 3000 (GE Healthcare). BST2-Fc and Fc were cova-
lently immobilized onto flow cells of a CM5 sensor chip by amine coupling 
according  to  the  manufacturer’s  instruction.  ILT7-Fc,  Fc,  and  26F8  in   
10 mM Hepes (pH 7.4), 150 mM NaCl, and 0.005% P20 were passed over 
the chip at 20 µl/min. To block the interactions between BST2 and ILT7, 
26F8 (120 µg/ml), IgG1 (120 µg/ml), or buffer was injected over BST2-Fc–
coated sensor chip before injection of ILT7-Fc (120 µg/ml).
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